Incretin-based Drugs and the Risk of Heart Failure
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2
diabetes) taken either alone or in combination with other anti-diabetic drugs are associated
with an increased risk of heart failure (HF) compared to other combinations of oral
hypoglycemic agents (OHA).
The investigators will carry out separate population based cohort studies using
administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts
will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs
entered the market, with follow-up until hospitalization for HF. Analyses will be done
separately for groups of patients with and without prior HF. The results from the separate
sites will be combined to provide an overall assessment of the risk of HF in users of
incretin-based drugs and by class of incretin-based drugs.
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network, Canada